Avalo Therapeutics shareholders approve Second Amended ESPP at 2026 annual meeting

Avalo Therapeutics, Inc.

ESPP share reserve set at 961,608 shares; annual evergreen of lesser of 4M shares or 1% of outstanding common stock through 2036.
Purchase price at 85% of FMV on either offering date or purchase date, whichever is lower; payroll deductions up to 15% of earnings.
All seven director nominees elected with >99% of votes cast in favor (e.g., Michael Heffernan: 21,101,978 for, 624 withheld).
Ratification of Ernst & Young as independent auditor approved with 22,513,332 for vs 153,320 against and 5,632 abstain.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Avalo Therapeutics, Inc. shareholders approved To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-02 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-02

Exact text from the filing

3. Proposal 3: To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. This proposal was approved by the votes indicated below. For Against Abstain Broker Non-Votes 22,513,332 153,320 5,632 —

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Avalo Therapeutics, Inc. shareholders approved To approve the Avalo Therapeutics, Inc. Second Amended and Restated 2016 Employee Stock Purchase Plan (A&R 2016 ESPP) at the 2026-06-02 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2026-06-02

Exact text from the filing

2. Proposal 2: To approve the A&R 2016 ESPP . This proposal was approved by the votes indicated below: For Against Abstain Broker Non-Votes 14,513,683 6,588,576 343 1,569,682

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Avalo Therapeutics, Inc. shareholders approved Election of seven nominees to the Board to hold office until the 2027 Annual Meeting of Stockholders and until their respective successors are elected and qualified. at the 2026-06-02 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-02

Exact text from the filing

1. Proposal 1: To elect seven nominees to the Board to hold office until the 2027 Annual Meeting of Stockholders and until their respective successors are elected and qualified. The following nominees were elected to the Board, with the voting results for each nominee as shown: Name For Withheld Broker Non-Votes Michael Heffernan 21,101,978 624 — Garry Neil, M.D. 21,101,093 1,509 — Rita Jain, M.D. 21,101,289 1,313 — Aaron Kantoff 21,078,660 23,942 — Gilla Kaplan, Ph.D. 21,093,059 9,543 — Kevin Lind 21,101,989 613 — Samantha Truex 21,089,975 12,627 —

View on SEC.gov

995 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001534120-26-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.